2022 MRM Talks: Dr. Michel L. Tremblay and Chu-Han Feng
The MRM Network presents: the MRM Talks. Join us every fourth Thursday at noon to learn more about stem cells and regenerative medicine. The webinar series will feature leading scientists in the field, including MRM Principal Investigators and external guest speakers.
For each seminar, we will also highlight the work of one MRM Trainee, who will present alongside our guest speaker.
In this edition of the MRM Talks:
Dr. Michel L. Tremblay,
Jeanne and Jean-Louis Lévesque Chair in Cancer Research
Distinguished James McGill Professor
President-Elect Academy of Sciences, Royal Society of Canada
Dept. of Biochemistry / Rosalind and Morris Goodman Cancer Institute
“Targeting tyrosine phosphatases in immunotherapies”
Ph.D. Candidate in Prof. Michel Tremblay’s Lab
“Biology of NK cells and Protein Tyrosine Phosphatases”
THURSDAY, March 24, 2022
12:00 – 1:00 PM
Missed the presentation? You can catch up on our Youtube Channel. NOTE: This video is only available to MRM members. Please contact us at email@example.com to verify your status and request access to the recording.
About the speakers:
Michel L. Tremblay, PhD, is a James McGill Distinguished Professor in the Departments of Biochemistry and an associate member in the departments of Microbiology & Immunology, Oncology and Medicine. He is a holder of the Jeanne and Jean-Louis Lévesque Chair in Cancer Research, at McGill University. A McMaster University (Ph.D.), he completed his M.Sc. graduate work at the Université de Sherbrooke (MSc) and his post-doctoral training at the National Institutes of Health in Bethesda, Maryland, in the field of embryonic stem cells. He was recruited in the dept. of Biochemistry at McGill U in 1992. He served as Director of the Rosalind and Morris Goodman Cancer Research Centre from 2000 to 2012, after which he stepped down to dedicate his efforts full-time to academic research. Dr. Tremblay’s laboratory focuses on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family, using both biochemical and genetic approaches. He has more than 30 patents and over 230 publications in the PTP field and is recognized for his work in relation to this gene family and its function in cancer, diabetes, and neuroscience. In 2012, he completed a one-year sabbatical at the Immunology Frontier Research Center, located on the campus of Osaka University, Osaka, Japan. Following his return to McGill he focus his work on cell therapeutics and in 2017 with colleagues at the MUHC and McGill Faculty of Medicine, he contributed to establishing the McGill Regenerative Medicine and served as its first director from February 2018 to Dec. 2021. Dr. Tremblay has contributed to several scientific boards of foundations and companies, including three companies, which he created, and he continues to pursue research projects in collaboration with the private sector in the field of Immunotherapy and cancer.
Chu-Han Feng is a fourth-year Ph.D. student in Dr. Michel L. Tremblay’s Lab. She developed her research interests in post-translational modifications in signal transduction in immune cells during her undergraduate studies under supervision by Dr. Anastasia Nijnik. After receiving her bachelor’s degree in interdepartmental honours immunology at McGill University, she followed another aspect of her research interests in cell-based cancer immunotherapy and joined Dr. Michel L. Tremblay’s lab, where she started her project on protein tyrosine phosphatases (PTPs) regulated human NK cell anti-cancer response.
We want to hear from you, and we welcome your suggestions for speakers!
If you are interested in hosting an invited speaker, please get in touch with us.